It has nothing to do with personal statements.
It has everything to do with pharmaceutical drug research, to treat people with difficulties that they are willing to pay a lot of money to treat.
And Forests efforts are paying off very well, with well executed research and teaming arrangements. I'm looking forward to Forest's statements tomorrow regarding MILNACIPRAN! Ans pehaps the FDA approval of another drug THIS WEEK!!
Remember, Dr. KRANZLER'S TYPING THE DATA REPORT NOW!!!!!!!
in a winded statement windley says please buy so me and my family can sell big. another one of those days when the guy on the radio says "and wall street cheered late day gains" and then you realize.... whoops! i am in ground hog day and my bane, frx, went down the crapper again...so long lemmings....till tomorrow!
Meanwhile, Jefferies & Co. analyst David Windley, who rates Forest a "Buy" with a $50 price target, said the stock's continued weakness presents a good buying opportunity.
Windley expects upside could be generated by decisions from the Food and Drug Administration on new drug applications for blood pressure drugs Azor, possibly by end of the week, and nebivolol, in early November.
In addition, data on several investigational drugs are expected in 2008, Windley said. He expressed optimism that the drugs Forest is pursuing are all apart of substantial markets, including schizophrenia and complicated skin infections.
With its drug candidate aclidinium for lung disease COPD, Windley said he was encouraged by midstage data, or Phase II results, released last week.
OTHER DRUGS ONLY liscensed for management od FIBRO
MILNACIPRAN going for qualification of indication for TREATMENT of FIBRO instead of just management
Clinically meaningful and statistically significant